银酸C-K通过调节微质-神经元相互作用来抑制Aβ寡合体诱导的阿尔茨海默病病理进展
Chenghu Xie1,2, Cunxin Zhang1,2, Kefeng Zhang1,2
1Department of Spine Surgery, Jining NO.1 People's Hospital Affiliated to Shandong First Medical University & Shandong Academy of Medical Sciences, China.
IBRO neuroscience reports
|June 13, 2025
概括
金色化物C-K (GCK) 通过直接降低粉样β毒性和间接调节大脑免疫细胞,有效地对抗阿尔茨海默病 (AD). 这种天然化合物为AD提供了一个有前途的多目标治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,有效治疗方法有限.
- 目前的疗法主要是缓解症状,突出了针对疾病进展的新策略的需要.
- 具有多目标作用的天然化合物对开发新的AD治疗有希望.
研究的目的:
- 为了研究金色化物C-K (GCK) 对阿尔茨海默病 (AD) 病理学的影响.
- 阐明GCK在β-粉样蛋白 (Aβ) 寡合体诱导的AD中的多目标调节机制.
- 评估GCK作为一种基于天然产品的AD疗法的潜力.
主要方法:
- 使用了BV2微质和HT22神经元的体外模型.
- 评估了细胞活力 (CCK-8),迁移 (划痕试验) 和亡 (附件V/PI染色).
- 分析了NF-κB信号通路和炎症性细胞因子 (TNF-α,IL-1β) 通过西方抹黑和条件介质策略.
主要成果:
- GCK显著改善了Aβ寡合体诱导的BV2细胞功能障碍,并抑制了前炎性细胞因子分泌.
- 在微质中,GCK抑制了NF-κB通路的激活.
- 在HT22神经元中,GCK直接降低了Aβ毒性,并通过微质调节提供间接的神经保护.
结论:
- GCK通过直接的神经保护和间接的微质调节来缓解AD病理,NF-κB抑制作为关键机制.
- 这项研究支持GCK作为一种潜在的多位治疗药物治疗AD.
- 需要进一步的体内研究来证实GCK在AD治疗中的有效性和安全性.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
09:12Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
15.8K
相关概念视频
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
